Chinese biotechs Bao Pharma & Biokin file for Hong Kong listings, Disc Medicine plans $200M offering, Rivus adds $57M to Series B & Crown Labs raises Revance bid to $3.65/share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback